Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19

The emerging upsurge of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has resulted in a global pandemic which originated in Wuhan city, China. The complicated virology of SARS CoV-2 makes it difficult to evaluate the therapeutic management for this infection. Drug repurposing is been...

Full description

Bibliographic Details
Main Authors:	Justin Jacob Abraham, I Jerlin Michelle, S A Shevaani, Kiran Kumar Rathinam, Muhasaparur Ganesan Rajanandh, Vijayakumar Thangavel Mahalingam
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Current Medicine Research and Practice
Subjects:	covid-19 cytokine release syndrome interleukin 6 monoclonal antibody sarilumab
Online Access:	http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=6;spage=280;epage=283;aulast=Abraham

Similar Items

Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19
by: I Jerlin Michelle, et al.
Published: (2021-01-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01)

Sarilumab use in severe Coronavirus Disease 2019 pneumonia
by: Ahmed M.A. El Fattah Amer, et al.
Published: (2023-01-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Polymyalgia Rheumatica Treated with Sarilumab
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
by: Vibeke Strand, et al.
Published: (2020-10-01)

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
by: Annett Klinder, et al.
Published: (2022-06-01)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
by: Wolfgang A. Schmidt, et al.
Published: (2023-10-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

Sarilumab use in severe SARS-CoV-2 pneumonia
by: Elisa Gremese, et al.
Published: (2020-10-01)

Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
by: Pranay Sinha, et al.
Published: (2020-10-01)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
by: Su-Yeon Yu, et al.
Published: (2022-12-01)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022-05-01)

Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19
by: Tatyana S. Kruglova, et al.
Published: (2021-11-01)

Interleukin-6 and Macular Edema: A Review of Outcomes with Inhibition
by: Janine Yunfan Yang, et al.
Published: (2023-02-01)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
by: Thomas Huizinga, et al.
Published: (2023-02-01)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
by: Luis Sainz, et al.
Published: (2023-11-01)

Outlook of IL-6 signaling blockade for COVID-19 pneumonia
by: Misato Hashizume
Published: (2020-10-01)

Immune-related adverse events of biological immunotherapies used in COVID-19
by: Daniela Baracaldo-Santamaría, et al.
Published: (2022-08-01)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
by: Qian Gao, et al.
Published: (2022-12-01)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
by: Cem Gabay, et al.
Published: (2020-04-01)

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages
by: Maaike C. Swets, et al.
Published: (2023-04-01)

Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)Research in context
by: Ilaria Mastrorosa, et al.
Published: (2023-03-01)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
by: Andrea Rubbert-Roth, et al.
Published: (2022-08-01)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-03-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
by: Emanuel Della-Torre, et al.
Published: (2021-04-01)

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial
by: Rosario García-Vicuña, et al.
Published: (2022-02-01)

Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
by: Steven Douedi, et al.
Published: (2020-01-01)

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19
by: N. V. Muravyeva, et al.
Published: (2022-07-01)

Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and meta-analysis of randomized controlled trials
by: Rong Peng, et al.
Published: (2023-08-01)

Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis
by: Kiran Godse
Published: (2017-01-01)

Development and Characterization of New Monoclonal Antibodies Against Porcine Interleukin-17A and Interferon-Gamma
by: Jean N. Manirarora, et al.
Published: (2022-02-01)

Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock
by: Marketa Bloomfield, et al.
Published: (2019-11-01)

Development and characterization of monoclonal antibodies specific for chicken interleukin-13 and their neutralizing effects in chicken primary monocytes
by: Atul A. Chaudhari, et al.
Published: (2020-02-01)